Olatuton (Octreotide Acetate)

Octreotide Acetate, the active ingredient in Olatuton, is a somatostatin analog presented as a strength/form for intramuscular use. It treats hormone‑secreting tumors and related endocrine disorders in adults. GNH USA supplies Olatuton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Olatuton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Olatuton is a somatostatin analog that modulates hormone‑secretion pathways in several endocrine conditions.

- Acromegaly: reduces excess growth‑hormone production and helps control disease activity. - Neuroendocrine tumours: controls tumour‑related hormone secretion and alleviates flushing and diarrhoea. - Carcinoid syndrome: diminishes flushing, wheezing and diarrhoea associated with serotonin excess. - VIPoma: lowers vasoactive intestinal peptide levels and reduces severe watery diarrhoea. - Post‑operative pancreatic fistula prevention: decreases pancreatic secretions after major abdominal surgery.

Adverse reactions to Olatuton are generally related to its hormonal inhibition and injection‑site tolerability.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Abdominal pain: cramp‑like discomfort. - Diarrhoea or constipation: altered bowel habits. - Injection‑site reactions: redness, swelling or bruising. - Headache: transient head discomfort. - Hyperglycaemia: elevated blood‑sugar levels.

Serious or Rare Side Effects: - Gallbladder disease: sludge or stones leading to biliary colic. - Pancreatitis: inflammation of the pancreas. - Severe hypoglycaemia: dangerously low blood‑sugar, especially in diabetic patients. - Cardiac arrhythmias: irregular heart rhythm. - Anaphylaxis: acute allergic reaction requiring immediate medical care.

When using Olatuton, clinicians should assess patient‑specific factors and monitor for known risks.

- Cardiovascular assessment: evaluate for existing heart disease before initiating therapy. - Glycaemic monitoring: check blood‑glucose levels in diabetic or pre‑diabetic patients. - Gallbladder evaluation: consider ultrasound screening for patients with a history of gallstones. - Pregnancy and lactation: avoid unless the potential benefit outweighs risk. - Renal or hepatic impairment: adjust monitoring frequency as organ function may affect drug clearance. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide may interact with several medicines that influence hormone levels or gastrointestinal motility.

Major Interactions (Avoid): - Insulin or oral hypoglycaics: may potentiate hypoglycaemia. - Cytochrome P450 3A4 inducers: can reduce octreotide exposure.

Moderate Interactions (Monitor Closely): - Somatostatin analogues other than Olatuton: additive hormonal suppression. - Proton‑pump inhibitors: may alter gastric pH and affect absorption of concomitant oral agents. - Antiplatelet or anticoagulant drugs: increased risk of injection‑site bleeding.